Publication of Prospectus

12 July 2018

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLYOR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO  SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the "Prospectus") in its final form that is published by OKYO Pharma Limited ("OKYO Pharma" or the "Company") in connection with the admission of the Company's entire issued share capital to listing on the standard segment of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange"). This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in the United States, Australia, Canada, Japan or in any other jurisdiction.

12 July 2018

OKYO Pharma Limited
(Incorporated and registered in Guernsey with registered number 65220)

Publication of Prospectus

The Company is pleased to announce today the publication of its Prospectus in relation to the admission of 523,395,417 ordinary shares of no par value each (the “Ordinary Shares”) to listing on the standard segment of the Official List of the FCA (under Chapter 14 of the Listing Rules of the FCA) and to trading on the Main Market of the London Stock Exchange (together, "Admission").

It is expected that Admission will become effective and that dealings will commence at 8 a.m. on 17 July 2018.

The Ordinary Shares are registered with ISIN GG00BD3FV870, SEDOL BD3FV87 and TIDM OKYO, and the Company’s LEI is 213800VVN5CB56Y15A05.

Hard copies of the Prospectus will be available during normal business hours from the Company's registered office at Martello Court, Admiral Park, St. Peter Port, Guernsey GY1 3HB and the offices of Cooley (UK) LLP at Dashwood, 69 Old Broad Street, London EC2M 1QS, and will be made available online at http://okyopharma.com/content/investor-centre/corporate-documents (subject to applicable securities laws).

An electronic copy of the Prospectus will also be submitted to the National Storage Mechanism and should be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM.

Highlights

  • The listing of the Company’s shares on AIM was cancelled on 23 March 2018, and on 10 January 2018, the Company changed its name to OKYO Pharma Corporation and adopted a bespoke investing policy to create a diversified portfolio of meaningful direct and indirect interests in life science and biotechnology opportunities.
  • On 21 February 2018, the Company announced that it had identified an opportunity to obtain (via assignment from Panetta) a licence from On Target Therapeutics LLC and a sub-licence from Tufts Medical Center Inc. (“Tufts”) of the right to exploit all of the intellectual property relating to rights claimed on patent WO2017014605, being claims in composition of matter and methodology for treating, inter alia, ocular inflammation, dry eye disease  and ocular neuropathic pain with Chemerin or a fragment of analog thereof and a lipid entity linked to the Chemerin or fragment or analog thereof (the “Chemerin Project”).
  • On 1 May 2018, the Company acquired the benefit of a licence from Tufts of the right to exploit all of the intellectual property relating to the development of the endogenous peptide BAM-8 (“BAM-8”).
  • On 9 March 2018, the Company sought and obtained the consent of shareholders to cancel its trading facility on AIM and to migrate to Guernsey (the “Migration”).
  • The Company identified the Chemerin Project as an initial business opportunity and will look to make further complementary acquisitions in the future. The Company wishes to differentiate itself by focusing on opportunities where clinical development timelines are short and where the management teams can benefit from the clinical development and commercialisation experience of its directors and senior management.
  • As such it is the intention that the Company will work closely with its retained clinicians with a view to generating incremental value for its shareholders.

Willy Simon, Executive Chairman of OKYO Pharma, said:

"We have made significant progress delivering on our targeted acquisition strategy of suitable investment candidates in the life science and biotechnology sector, and the Chemerin Project and, most recently, the BAM-8 Project are a prime examples thereof. 

Whilst the Chemerin Project will be the initial focus of the Company, BAM-8 is an exciting prospect and one which, with time, we intend to examine as a potential non-opioid analgesic.  

The board would like to thank our shareholders for their support and patience as it has taken longer than initially anticipated to re-admit due to the complexities of the Migration process. We look forward to providing updates on our progress in the weeks and months ahead."

Enquiries:

OKYO Pharma Limited

Willy Simon

 

+44 (0)20 7382 8300

Stockdale Securities Limited (Broker)

Andy Crossley

Antonio Bossi

Owen Matthews

 

+44 (0)20 7601 6100

 

 

 

For further information, please visit the Company's website at http://okyopharma.com/.

Forward-looking statements

Certain statements in this announcement constitute ''forward-looking statements''. Forward-looking statements include statements concerning the plans, objectives, goals, strategies and future operations and performance of the Company and the assumptions underlying these forward-looking statements. The Company uses the words ''anticipates'', ''estimates'', ''expects'', ''believes'', ''intends'', ''plans'', ''may'', ''will'', ''should'', and any similar expressions to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the Company's actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company is not obliged, and does not intend, to update or to revise any forward-looking statements, whether as a result of new information, future events or otherwise except to the extent required by any applicable law or regulation. All subsequent written or oral forward-looking statements attributable to the Company, or persons acting on behalf of the Company, are expressly qualified in their entirety by the cautionary statements contained throughout this announcement. As a result of these risks, uncertainties and assumptions, a prospective investor should not place undue reliance on these forward-looking statements.

 

Download PDF Version: